Ji Yun Kim
About Ji Yun Kim
Ji Yun Kim serves as the Director of Clinical Biomarkers at Arcus Biosciences, where she specializes in PD biomarker assay development and validation. With extensive experience in the pharmaceutical and academic sectors, she has held various roles at notable organizations including Bayer Pharmaceuticals and Stanford University School of Medicine.
Work at Arcus Biosciences
Ji Yun Kim serves as the Director of Clinical Biomarkers at Arcus Biosciences, a position she has held since 2021. In this role, she specializes in the development, transfer, and validation of pharmacodynamic (PD) biomarker assays. She collaborates with contract research organizations to ensure the successful implementation of clinical biomarker strategies. Her work focuses on generating data packages that support decision-making in clinical projects, particularly in late-stage development.
Education and Expertise
Ji Yun Kim earned her Ph.D. in Biochemistry and Cell Biology from The Johns Hopkins University School of Medicine. She also holds a Bachelor of Science degree in Biochemistry from the University of Iowa. Additionally, she completed postdoctoral training in Immunology and Cell Biology at Stanford University School of Medicine. Her educational background provides a strong foundation for her expertise in clinical biomarker assay development and leukocyte biology.
Background
Ji Yun Kim has a diverse professional background in the pharmaceutical and academic sectors. She began her career as a Postdoctoral Fellow at Stanford University School of Medicine from 1997 to 2002. Following her postdoctoral training, she worked as a Research Scientist at Stanford for four years. She then held various positions at Bayer Pharmaceuticals, including Staff Scientist and Senior Staff Scientist, before transitioning to Gilead Sciences and Theravance Biopharma US, Inc. Her extensive experience spans over two decades in biomarker sciences.
Achievements
Throughout her career, Ji Yun Kim has developed and implemented clinical biomarker strategies in late-stage clinical development projects. She has led the development of in vitro and ex vivo studies to generate comprehensive data packages for clinical biomarker projects. Her focus on leukocyte biology, particularly migration and adhesion, supports drug mechanism of action studies. Additionally, she has expertise in managing key opinion leaders and fostering academic collaborations in the field of clinical biomarkers.